Our Leadership

Modus Therapeutics has a Board of Directors and Leadership Team with extensive experience of drug development, partnering and business in life science. This in combination with skilled external expertise, as consultants or advisors, creates a strong team with experience in taking pharmaceutical products to the market.

Board of Directors Leadership Team

Board of Directors

Björn Sjöstrand
Björn Sjöstrand
Chairman

Bjorn Sjöstrand has extensive experience gained from the vaccines industry in several international executive positions. He is currently running his own management consulting business; holds several board positions in both private and public companies; and is founder of a number of biotech companies.

Mats Wahlgren
Mats Wahlgren
Board Member & Chief Scientific Officer

Professor Mats Wahlgren investigates the molecular pathogenesis of parasitic diseases. Previous positions include directorship of MTC (KI), the Multilateral Initiative on Malaria and the Infection and Vaccinology Programme (SSF).

Viktor Drvota M.D, Ph.D
Viktor Drvota M.D, Ph.D
Board Member

Viktor Drvota is Deputy CEO and CIO at Karolinska Development. He has more than 13 years of Venture Capital experience with several investments, significant fundraisings, IPOs and exits.

Torsten Goesch M.D Ph.D
Torsten Goesch M.D Ph.D
Board Member

Dr. Torsten Goesch has been the director of Rosetta Capital secondary life science investor since 2002, where he is responsible for the management of several Rosetta Capital investments.

Tomas Odergren M.D, Ph.D
Tomas Odergren M.D, Ph.D
Board Member

Dr. Tomas Odergren is an M.D and a Ph.D with a specialist interest in neurology. Dr. Odergren currently holds the position as Chief Expert at H Lundbeck A/S in Denmark.

Dr Miroslav Reljanović
Dr Miroslav Reljanović
Board Member

Dr Miroslav Reljanović is a medical doctor and a board-certified neurologist. He founded Ergomed in 1997 and led the Company through a successful IPO on the AIM market of the London Stock Exchange in 2014.

Dr. Mårten Steen
Dr. Mårten Steen
Board Member

Dr. Mårten Steen is a medical doctor and Partner of HealthCap. Previously, he worked with business development at Merck Serono and has pursued research in the field of coagulation at Lund University and Novo Nordisk, rendering him a PhD in Clinical Chemistry in 2003.

Leadership Team

Ellen K. Donnelly, Ph.D
Ellen K. Donnelly, Ph.D
Chief Executive Officer

Ellen K. Donnelly, Ph.D., joined Modus Therapeutics April 2017 from Pfizer, Inc., where she held various leadership positions in Clinical Operations; Project and Portfolio Management; and Research.

Dr. John Öhd
Dr. John Öhd
Chief Medical Officer

Dr. Öhd joined Modus at Chief Medical Officer in March 2018 from Medivir AB, where he was CMO and a member of the company’s Executive Management team. Before taking up his current position, John was Medivir’s Director of Clinical R&D.

Mats Wahlgren
Mats Wahlgren
Board Member & Chief Scientific Officer

Professor Mats Wahlgren investigates the molecular pathogenesis of parasitic diseases. Previous positions include directorship of MTC (KI), the Multilateral Initiative on Malaria and the Infection and Vaccinology Programme (SSF).